Kiniksa's insider sale totaled $14,330,278, but the report does not name the seller or explain the reason. It gives no sign of a change in the company's business, so the sale alone does not change the outlook.
The report does not say who sold the shares or why. It gives no update on Kiniksa's medicines, sales, or finances, so the sale alone does not show a change in the company's outlook.
Follow Kiniksa Pharmaceuticals International (KNSA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for KNSA